Jacobson Pharma Corporation 2633.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.92

-0.54%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in HKD, from our data supplier.

FY2026

Revenue

HK$1.57bn

FY2017FY2026

Net income

HK$301.6m

FY2017FY2026

Free cash flow

HK$200.5m

FY2017FY2026

Shareholders' equity

HK$2.32bn

FY2017FY2026

Income statement

Fiscal years

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	HK$1.57bn	HK$1.58bn	HK$1.47bn	HK$1.79bn	HK$1.60bn	HK$1.45bn	HK$1.57bn	HK$1.48bn	HK$1.55bn	HK$1.26bn
Gross profit	HK$677.9m	HK$692.9m	HK$620.5m	HK$747.2m	HK$620.5m	HK$534.1m	HK$669.8m	HK$674.7m	HK$617.7m	HK$556.9m
Research and development	HK$115,000	—	—	HK$1.2m	HK$6.6m	HK$1.8m	HK$3.7m	HK$2.6m	HK$2.3m	HK$6.3m
Operating income	HK$353.2m	HK$414.6m	HK$333.1m	HK$319.1m	HK$222.9m	HK$185.5m	HK$295.4m	HK$339.1m	HK$280.1m	HK$254.2m
Net income	HK$301.6m	HK$300.8m	HK$267.0m	HK$251.0m	HK$177.7m	HK$173.7m	HK$215.6m	HK$250.6m	HK$202.3m	HK$179.3m
Diluted earnings per share	0.15	0.15	0.13	0.13	0.09	0.09	0.11	0.13	0.10	0.10

Balance sheet

At each fiscal year end

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Total assets	HK$3.56bn	HK$3.65bn	HK$3.49bn	HK$5.38bn	HK$4.76bn	HK$4.87bn	HK$4.58bn	HK$4.26bn	HK$3.61bn	HK$2.97bn
Cash and short-term investments	HK$369.9m	HK$509.0m	HK$411.9m	HK$1.04bn	HK$478.7m	HK$480.4m	HK$425.7m	HK$689.3m	HK$704.6m	HK$404.1m
Total liabilities	HK$1.22bn	HK$1.17bn	HK$1.09bn	HK$2.12bn	HK$1.80bn	HK$2.01bn	HK$1.97bn	HK$1.57bn	HK$1.60bn	HK$1.20bn
Debt	HK$910.9m	HK$773.2m	HK$749.4m	HK$1.60bn	HK$1.41bn	HK$1.65bn	HK$1.07bn	HK$1.30bn	HK$1.35bn	HK$938.0m
Shareholders' equity	HK$2.32bn	HK$2.45bn	HK$2.37bn	HK$2.74bn	HK$2.49bn	HK$2.39bn	HK$2.54bn	HK$2.65bn	HK$1.98bn	HK$1.75bn
Shares outstanding	2,000m	1,996m	1,984m	1,911m	1,919m	1,916m	1,917m	1,931m	1,931m	1,816m

Cash flow

Fiscal years

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Cash from operations	HK$336.7m	HK$526.8m	HK$484.4m	HK$648.2m	HK$409.8m	HK$411.3m	HK$375.6m	HK$395.7m	HK$243.0m	HK$163.5m
Capital spending	−HK$136.2m	−HK$248.4m	−HK$129.5m	−HK$63.0m	−HK$63.9m	−HK$63.4m	−HK$84.4m	−HK$44.1m	−HK$86.9m	−HK$92.4m
Free cash flow	HK$200.5m	HK$278.4m	HK$354.9m	HK$585.2m	HK$345.9m	HK$348.0m	HK$291.2m	HK$351.6m	HK$156.1m	HK$71.2m
Dividends paid	−HK$315.0m	−HK$59.6m	−HK$93.6m	−HK$104.0m	−HK$51.7m	−HK$63.2m	−HK$100.2m	−HK$88.7m	−HK$41.8m	−HK$239.3m

Latest quarters

By quarter end

	Mar 2026	Sept 2025	Mar 2025	Sept 2024	Mar 2024	Sept 2023	Mar 2023	Sept 2022
Revenue	HK$802.9m	HK$766.6m	HK$766.9m	HK$810.0m	HK$752.9m	HK$714.9m	HK$968.2m	HK$817.4m
Gross profit	HK$340.1m	HK$337.8m	HK$341.5m	HK$351.5m	HK$319.4m	HK$301.1m	HK$406.7m	HK$340.4m
Operating income	HK$184.4m	HK$183.4m	HK$182.5m	HK$195.8m	HK$167.2m	HK$138.5m	HK$167.0m	HK$152.1m
Net income	HK$159.6m	HK$142.0m	HK$160.5m	HK$140.3m	HK$112.9m	HK$125.8m	HK$114.9m	HK$136.2m
Diluted earnings per share	0.08	0.07	0.08	0.07	0.06	0.07	0.06	0.07
Cash from operations	HK$98.0m	HK$238.0m	HK$257.0m	HK$277.0m	HK$218.0m	HK$294.0m	HK$336.0m	HK$311.0m
Capital spending	−HK$71.0m	−HK$64.0m	−HK$162.0m	−HK$86.0m	−HK$65.0m	−HK$64.0m	−HK$49.0m	−HK$13.0m
Free cash flow	HK$27.0m	HK$174.0m	HK$95.0m	HK$191.0m	HK$153.0m	HK$230.0m	HK$287.0m	HK$298.0m
Total assets	HK$3.56bn	HK$3.53bn	HK$3.65bn	HK$3.61bn	HK$3.49bn	HK$3.99bn	HK$5.38bn	HK$5.06bn
Cash and short-term investments	HK$369.9m	HK$395.1m	HK$509.0m	HK$563.8m	HK$411.9m	HK$871.0m	HK$1.04bn	HK$860.4m
Debt	HK$884.0m	HK$934.4m	HK$773.2m	HK$699.9m	HK$749.4m	HK$1.31bn	HK$1.60bn	HK$1.56bn
Shareholders' equity	HK$2.32bn	HK$2.23bn	HK$2.45bn	HK$2.43bn	HK$2.37bn	HK$2.28bn	HK$2.74bn	HK$2.53bn

Financial ratios

Data as of 28 Oct 2026

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Gross margin	43.2%	43.9%	42.3%	41.8%	38.9%	36.9%	—	—
Operating margin	22.5%	26.3%	22.7%	17.6%	14.0%	12.8%	—	—
Net margin	19.2%	19.1%	18.2%	14.1%	11.1%	12.0%	—	—
Return on equity	13.0%	12.3%	11.3%	9.2%	7.1%	7.3%	—	—
Return on assets	8.5%	8.3%	7.7%	4.7%	3.7%	3.6%	—	—
Free cash flow yield	24.8%	40.7%	32.4%	39.0%	25.8%	25.9%	—	—
Revenue growth	-0.5%	7.4%	-17.8%	11.9%	10.3%	-8.0%	—	—
Earnings growth	0.3%	12.7%	6.3%	41.3%	2.3%	-19.4%	—	—
Current ratio	1.37x	1.88x	2.59x	2.68x	1.43x	1.33x	—	—
Debt to equity	0.38x	0.30x	0.31x	0.58x	0.55x	0.68x	—	—
Equity ratio	65.0%	67.3%	68.0%	50.9%	52.4%	49.1%	—	—
Interest coverage	11.50x	10.03x	4.23x	5.10x	8.68x	6.15x	—	—
R&D as a share of sales	0.0%	—	—	0.1%	0.4%	0.1%	0.2%	0.2%
Buybacks as a share of market value	-0.2%	-0.6%	-3.8%	0.4%	-0.2%	0.1%	—	—

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	-4.2%	1.7%	3.8%
Operating income	3.4%	13.7%	6.1%
Net income	6.3%	11.7%	7.6%

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	43.6%	42.8%	41.2%	42.1%
Operating margin	24.4%	22.2%	19.4%	19.5%
Net margin	19.1%	17.5%	15.6%	15.1%

Valuation history

At each fiscal year end

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Price to earnings	6.2	8.6	7.7	4.9	7.1	5.0	0.3
Price to sales	1.2	1.6	1.4	0.7	0.8	0.6	0.0

Dividends and splits

Per share, in the currency the company pays

Paid for 9 years. Last went ex-dividend on 7 Sept 2026.

	FY2027	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Paid in the year	0.048	0.098	0.065	0.049	0.055	0.027	0.033	0.05

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Jacobson Pharma Corporation 2633.HK · HKD

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology